Myeloma Paper of the Day, May 28th, suggested by Robert Orlowski
Robert Orlowski shared on X:
“Myeloma Paper of the Day: Retrospective Memorial Sloan Kettering study suggests the use of corticosteroids or tocilizumab in context of CAR T-cell therapy for relapsed/refractory myeloma does not impact PFS and OS.”
Source: Robert Orlowski/X
Authors: Bruno Almeida Costa, Jessica Flynn, Noriko Nishimura, Sean M. Devlin, Tasmin Farzana, Sridevi Rajeeve, David J. Chung, Heather J. Landau, Oscar B. Lahoud, Michael Scordo, Gunjan L. Shah, Hani Hassoun, Kylee Maclachlan, Malin Hultcrantz, Neha Korde, Alexander M. Lesokhin, Urvi A. Shah, Carlyn R. Tan, Sergio A. Giralt, Saad Z. Usmani, Karthik Nath and Sham Mailankody
Other insights by Robert Orlowski on OncoDaily.
Robert Orlowski holds multiple positions at The University of Texas MD Anderson Cancer Center, including Chairman, Ad Interim Director of Myeloma, and Professor of Medicine in the Departments of Lymphoma/Myeloma and Experimental Therapeutics within the Division of Cancer Medicine.
Additionally, he chairs the SWOG Barlogie/Salmon Myeloma Committee, which is part of the National Clinical Trials Network, dedicated to advancing new therapies and understanding the biology of myeloma.
